Please login to the form below

Not currently logged in
Email:
Password:

Shire set to make move for Cubist

Shire Pharmaceuticals is planning a takeover of US-based Cubist Pharmaceuticals in a multi-billion pound deal, according to a UK media report

Shire Pharmaceuticals is planning takeover of US-based Cubist Pharmaceuticals in a multi-billion pound deal, according to a UK media report.

An article in The Daily Telegraph claims industry rumours are suggesting that Shire approached Cubist about a month ago with a $44.5-a-share deal, and that the two companies have been in discussions since.

Shire, which acquired Advanced BioHealing last week in a £460m deal, is reported to be keen to expand as a way fending off potential bidders itself.

Cubist sells an antibiotic called Cubicin, which is used to treat complex skin infections and the superbug MRSA.

Speaking to PMLiVE, Shire said it declines to comment on industry speculation.

Cubist was available to comment at the time of writing.

24th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics